Targeting the immune system with nanomaterials is an intensely active area of research. Specifically, the capability to induce immunosuppression is a promising complement for drug delivery and regenerative medicine therapies. Many novel strategies for immunosuppression rely on nanoparticles as delivery vehicles for small-molecule immunosuppressive compounds. As a consequence, efforts in understanding the mechanisms in which nanoparticles directly interact with the immune system have been overshadowed. The immunological activity of nanoparticles is dependent on the physiochemical properties of the nanoparticles and its subsequent cellular internalization. As the underlying factors for these reactions are elucidated, more nanoparticles may be engineered and evaluated for inducing immunosuppression and complementing immunosuppressive drugs. This review will briefly summarize the state-of-the-art and developments in understanding how nanoparticles induce immunosuppressive responses, compare the inherent properties of nanomaterials which induce these immunological reactions, and comment on the potential for using nanomaterials to modulate and control the immune system.
HartonoCMuthukumarTSuthanthiranM. Immunosuppressive drug therapy. Cold Spring Harb Perspect Med2013; 3: a015487–a015487.
2.
GummerJFIkonenTMorrisRE. New immunosuppressive drugs: a review. J Am Soc Nephrol1999; 10: 15–15.
3.
van GelderTvan SchaikRHHesselinkDA. Pharmacogenetics and immunosuppressive drugs in solid organ transplantation. Nat Rev Nephrol2014; 10: 725–731.
4.
GharagozlooMMajewskiSFoldvariM. Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction. Nanomed Nanotechnol Biol Med2015; 11: 1003–1018.
5.
GuadaMSebastianVIrustaSFeijooEDios-VieitezMDBlanco-PrietoMJ. Lipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity. Int J Nanomed2015; 10: 6541–6553.
IlinskayaANDobrovolskaiaMA. Immunosuppressive and anti-inflammatory properties of engineered nanomaterials. Br J Pharmacol2014; 171: 3988–4000.
8.
XuWLingPXZhangTM. Toward immunosuppressive effects on liver transplantation in rat model: tacrolimus loaded poly(ethylene glycol)-poly(D,L-lactide) nanoparticle with longer survival time. Int J Pharm2014; 460: 173–180.
9.
BroomeAMDixitSLeveyNAtkinsonCNadigS. Towards targeted drug delivery in transplantation: use of immunosuppressant nanoparticle therapy. Am J Transplant2014; 14: 63–64.
MaldonadoRALaMotheRAFerrariJDZhangAHRossiRJKoltePNGrisetAPO’NeilCAltreuterDHBrowningEJohnstonLFarokhzadOCLangerRScottDWvon AndrianUHKishimotoTK. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc Natl Acad Sci USA2015; 112: E156–E165.
12.
ZhangPPChiuYCTostanoskiLHJewellCM. Polyelectrolyte multilayers assembled entirely from immune signals on gold nanoparticle templates promote antigen-specific T cell response. ACS Nano2015; 9: 6465–6477.
13.
WangJZhuRRSunDMSunXYGengZSLiuHWangSL. Intracellular uptake of curcumin-loaded solid lipid nanoparticles exhibit anti-inflammatory activities superior to those of curcumin through the NF-kappa B signaling pathway. J Biomed Nanotechnol2015; 11: 403–415.
14.
WangJWangHYZhuRRLiuQFeiJWangSL. Anti-inflammatory activity of curcumin-loaded solid lipid nanoparticles in IL-1 beta transgenic mice subjected to the, lipopolysaccharide-induced sepsis. Biomaterials2015; 53: 475–483.
15.
SilvaCORijoPMolpeceresJFigueiredoIVAscensaoLFernandesASRobertoAReisCP. Polymeric nanoparticles modified with fatty acids encapsulating betamethasone for anti-inflammatory treatment. Int J Pharm2015; 493: 271–284.
16.
ElderA. How do nanotubes suppress T cells?Nat Nanotechnol2009; 4: 409–410.
17.
ShvedovaAAKaganVE. The role of nanotoxicology in realizing the ‘helping without harm’ paradigm of nanomedicine: lessons from studies of pulmonary effects of single-walled carbon nanotubes. J Intern Med2010; 267: 106–118.
18.
GernandJMCasmanEA. A meta-analysis of carbon nanotube pulmonary toxicity studies—how physical dimensions and impurities affect the toxicity of carbon nanotubes. Risk Anal2014; 34: 583–597.
19.
HandyRDShawBJ. Toxic effects of nanoparticles and nanomaterials: implications for public health, risk assessment and the public perception of nanotechnology. Health Risk Soc2007; 9: 125–144.
20.
ZakrzewskiJLvan den BrinkMRMHubbellJA. Overcoming immunological barriers in regenerative medicine. Nat Biotechnol2014; 32: 786–794.
21.
Clemente-CasaresXSantamariaP. Nanomedicine in autoimmunity. Immunol Lett2014; 158: 167–174.
22.
JanewayCAJTraversPWalportM. Principals of inate and adaptive immunity. In: Immunobiology: the immune system in health and disease, New York, NY: Garland Science, 2001.
23.
AggarwalPHallJBMcLelandCBDobrovolskaiaMAMcNeilSE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev2009; 61: 428–437.
24.
LukBTZhangL. Cell membrane-camouflaged nanoparticles for drug delivery. J Control Release2015; 220(Pt B): 600–607.
25.
CaraccioloGPalchettiSColapicchioniVDigiacomoLPozziDCapriottiALLa BarberaGLaganaA. Stealth effect of biomolecular corona on nanoparticle uptake by immune cells. Langmuir2015; 31: 10764–10773.
26.
DobrovolskaiaMAAggarwalPHallJBMcNeilSE. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm2008; 5: 487–495.
27.
DobrovolskaiaMAMcneilSE. Immunological properties of engineered nanomaterials. Nat Nanotechnol2007; 2: 469–478.
28.
ZolnikBSGonzalez-FernandezASadriehNDobrovolskaiaMA. Minireview: nanoparticles and the immune system. Endocrinology2010; 151: 458–465.
ManolovaVFlaceABauerMSchwarzKSaudanPBachmannMF. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol2008; 38: 1404–1413.
33.
TenzerSDocterDKuharevJMusyanovychAFetzVHechtRSchlenkFFischerDKiouptsiKReinhardtCLandfesterKSchildHMaskosMKnauerSKStauberRH. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol2013; 8: 772–781.
34.
LundqvistMStiglerJEliaGLynchICedervallTDawsonKA. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A2008; 105: 14265–14270.
35.
MirshafieeVKimRParkSMahmoudiMKraftML. Impact of protein pre-coating on the protein corona composition and nanoparticle cellular uptake. Biomaterials2016; 75: 295–304.
36.
GunawanCLimMMarquisCPAmalR. Nanoparticle-protein corona complexes govern the biological fates and functions of nanoparticles. J Mater Chem B2014; 2: 2060–2083.
37.
JiaoQLiLWMuQXZhangQ. Immunomodulation of nanoparticles in nanomedicine applications. Biomed Res Inter2014; 2014: 1–19.
38.
FoersterJBachmanM. Beyond passive immunization: toward a nanoparticle-based IL-17 vaccine as first in class of future immune treatments. Nanomedicine2015; 10: 1361–1369.
39.
TalekarMTranTHAmijiM. Translational nano-medicines: targeted therapeutic delivery for cancer and inflammatory diseases. AAPS J2015; 17: 813–827.
40.
IlinskayaADobrovolskaiaMA. Immunosuppressive and anti-inflammatory properties of engineered nanomaterials. Br J Pharmacol2014; 171: 13–13.
41.
DykmanLKhlebtsovN. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem Soc Rev2012; 41: 2256–2282.
42.
ZhangXY. Gold nanoparticles: recent advances in the biomedical applications. Cell Biochem Biophys2015; 72: 771–775.
43.
PissuwanDValenzuelaSMKillingsworthMCXuXDCortieMB. Targeted destruction of murine macrophage cells with bioconjugated gold nanorods. J Nanopart Res2007; 9: 1109–1124.
44.
ChithraniBDGhazaniAAChanWCW. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett2006; 6: 662–668.
45.
ChenHDorriganASaadSHareDJCortieMBValenzuelaSM. In vivo study of spherical gold nanoparticles: inflammatory effects and distribution in mice. PLoS One2013; 8: e58208–e58208.
46.
LinICLiangMTLiuTYMonteiroMJTothI. Cellular transport pathways of polymer coated gold nanoparticles. Nanomed Nanotechnol Biol Med2012; 8: 8–11.
47.
PetrarcaCClementeEAmatoVPedataPSabbioniEBernardiniGIavicoliICorteseSNiuQOtsukiTPaganelliRDi GioacchinoM. Engineered metal based nanoparticles and innate immunity. Clin Mol Allergy2015; 13: 13–13.
48.
SurAPradhanBBanerjeeAAichP. Immune activation efficacy of indolicidin is enhanced upon conjugation with carbon nanotubes and gold nanoparticles. PLoS One2015; 10: e0123905–e0123905.
49.
FytianosKRordriguez-LorenzoLBlankFvon GarnierCPetri-FinkARothen-RutishauserB. Surface modified gold nanoparticles to specifically target lung immune cells in vitro. J Aerosol Med Pulm Drug Deliv2015; 28: A35–A35.
50.
KendallELiptrottNOwenA. Investigating the interaction of gold nanoparticles with the human immune system. Scott Med J2014; 59: E34–E34.
51.
GarciaCPSumbayevVGillilandDYasinskaIMGibbsBFMehnDCalzolaiLRossiF. Microscopic analysis of the interaction of gold nanoparticles with cells of the innate immune system. Sci Rep2013; 3: 1–7.
52.
ThakorASJokerstJZavaletaCMassoudTFGambhirSS. Gold Nanoparticles: a revival in precious metal administration to patients. Nano Lett2011; 11: 4029–4036.
53.
JamesLRAXuZQSluyterRHawksworthELKelsoCLaiBPatersonDJde JongeMDDixonNEBeckJLRalphSFDillonCT. An investigation into the interactions of gold nanoparticles and anti-arthritic drugs with macrophages, and their reactivity towards thioredoxin reductase. J Inorg Biochem2015; 142: 28–38.
HuangKYMaHLLiuJHuoSDKumarAWeiTZhangXJinSBGanYLWangPCHeSTZhangXNLiangXJ. Size-dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano2012; 6: 4483–4493.
56.
GoodmanCMMcCuskerCDYilmazTRotelloVM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjugate Chem2004; 15: 897–900.
57.
FernandezTDPearsonJRLealMPTorresMJBlancaMMayorgaCLe GuevelX. Intracellular accumulation and immunological properties of fluorescent gold nanoclusters in human dendritic cells. Biomaterials2015; 43: 1–12.
58.
LiptrottNJKendallENievesDJFarrellJRannardSFernigDGOwenA. Partial mitigation of gold nanoparticle interactions with human lymphocytes by surface functionalization with a ‘mixed matrix’. Nanomedicine2014; 9: 2467–2479.
59.
DengZJLiangMTMonteiroMTothIMinchinRF. Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation. Nat Nanotechnol2011; 6: 39–44.
60.
FytianosKRodriguez-LorenzoLCliftMJBlankFVanheckeDvon GarnierCPetri-FinkARothen-RutishauserB. Uptake efficiency of surface modified gold nanoparticles does not correlate with functional changes and cytokine secretion in human dendritic cells in vitro. Nanomedicine2015; 11: 633–644.
61.
GreulichCDiendorfGessmannJSimonTHabijanTEggelerGSchildhauerTAEppleMKollerM. Cell type-specific responses of peripheral blood mononuclear cells to silver nanoparticles. Acta Biomaterialia2011; 7: 3505–3514.
62.
ShinSHYeMKKimHSKangHS. The effects of nano-silver on the proliferation and cytokine expression by peripheral blood mononuclear cells. Int Immunopharmacol2007; 7: 1813–1818.
63.
YenHJHsuSHTsaiCL. Cytotoxicity and immunological response of gold and silver nanoparticles of different sizes. Small2009; 5: 1553–1561.
BholKCSchechterPJ. Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of inflammatory cells in a murine model of allergic contact dermatitis. Br J Dermatol2005; 152: 1235–1242.
66.
BholKCSchechterPJ. Effects of nanocrystalline silver (NPI 32101) in a rat model of ulcerative colitis. Dig Dis Sci2007; 52: 2732–2742.
67.
LiaoMHJanTR. A single exposure to iron oxide nanoparticles attenuates antigen-specific antibody production and T-cell reactivity in ovalbumin-sensitized BALB/c mice. Int J Nanomed2011; 6: 1229–1235.
68.
ShenCCLiangHJWangCCLiaoMHJanTR. Iron oxide nanoparticles suppressed T helper 1 cell-mediated immunity in a murine model of delayed-type hypersensitivity. Int J Nanomed2012; 7: 2729–2729.
69.
WuHYChungMCWangCCHuangCHLiangHJJanTR. Iron oxide nanoparticles suppress the production of IL-1beta via the secretory lysosomal pathway in murine microglial cells. Part Fibre Toxicol2013; 10: 46–46.
70.
BlankFGerberPRothen-RutishauserBSakulkhuUSalaklangJDe PeyerKGehrPNicodLPHofmannHGeiserTPetri-FinkAVon GarnierC. Biomedical nanoparticles modulate specific CD4(+) T cell stimulation by inhibition of antigen processing in dendritic cells. Nanotoxicology2011; 5: 606–621.
XueYLuanQFYangDYaoXZhouKB. Direct evidence for hydroxyl radical scavenging activity of cerium oxide nanoparticles. J Phys Chem C2011; 115: 4433–4438.
74.
HeckmanKLDeCoteauWEstevezAReedKJCostanzoWSanfordDLeiterJCClaussJKnappKGomezC. Custom cerium oxide nanoparticles protect against a free radical mediated autoimmune degenerative disease in the brain. ACS Nano2013; 7: 10582–10596.
75.
HirstSMKarakotiASTylerRDSriranganathanNSealSReillyCM. Anti-inflammatory properties of cerium oxide nanoparticles. Small2009; 5: 2848–2856.
76.
ColonJHsiehNFergusonAKupelianPSealSJenkinsDWBakerCH. Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. Nanomed Nanotechnol Biol Med2010; 6: 698–705.
77.
LeeSSSongWSChoMJPuppalaHLNguyenPZhuHGSegatoriLColvinVL. Antioxidant properties of cerium oxide nanocrystals as a function of nanocrystal diameter and surface coating. ACS Nano2013; 7: 9693–9703.
78.
SongWHZhangJYGuoJZhangJHDingFLiLYSunZT. Role of the dissolved zinc ion and reactive oxygen species in cytotoxicity of ZnO nanoparticles. Toxicol Lett2010; 199: 389–397.
79.
LipovskyANitzanYGedankenALubartR. Antifungal activity of ZnO nanoparticles—the role of ROS mediated cell injury. Nanotechnology2011; 22: 1–5.
80.
HanleyCThurberAHannaCPunnooseAZhangJHWingettDG. The influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. Nanoscale Res Lett2009; 4: 1409–1420.
81.
HanleyCThurberAHannaCPunnooseAZhangJWingettDG. The influences of cell type and ZnO nanoparticle size on immune cell cytotoxicity and cytokine induction. Nanoscale Res Lett2009; 4: 1409–1420.
82.
SaptarshiSRFeltisBNWrightPFALopataAL. Investigating the immunomodulatory nature of zinc oxide nanoparticles at sub-cytotoxic levels in vitro and after intranasal instillation in vivo. J Nanobiotechnol2015; 13: 1–11.
83.
FeltisBNOKeefeSJHarfordAJPivaTJTurneyTWWrightPFA. Independent cytotoxic and inflammatory responses to zinc oxide nanoparticles in human monocytes and macrophages. Nanotoxicology2012; 6: 757–765.
84.
KimCSNguyenHDIgnacioRMKimJHChoHCMaengEHKimYRKimMKParkBKKimSK. Immunotoxicity of zinc oxide nanoparticles with different size and electrostatic charge. Int J Nanomed2014; 9: 195–205.
85.
Andersson-WillmanBGehrmannUCansuZBuerki-ThurnherrTKrugHFGabrielssonSScheyniusA. Effects of subtoxic concentrations of TiO2 and ZnO nanoparticles on human lymphocytes, dendritic cells and exosome production. Toxicol Appl Pharmacol2012; 264: 94–103.
86.
TuomelaSAutioRBuerki-ThurnherrTArslanOKunzmannAAndersson-WillmanBWickPMathurSScheyniusAKrugHFFadeelBLahesmaaR. Gene expression profiling of immune-competent human cells exposed to engineered zinc oxide or titanium dioxide nanoparticles. PLoS One2013; 8: e68415–e68415.
87.
MoonEYYiGHKangJSLimJSKimHMPyoS. An increase in mouse tumor growth by an in vivo immunomodulating effect of titanium dioxide nanoparticles. J Immunotoxicol2011; 8: 56–67.
88.
MitchellLALauerFTBurchielSWMcDonaldJD. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat Nanotechnol2009; 4: 451–456.
YudohKKarasawaRMasukoKKatoT. Water-soluble fullerene (C60) inhibits the development of arthritis in the rat model of arthritis. Int J Nanomed2009; 4: 217–225.
91.
GharbiNPressacMHadchouelMSzwarcHWilsonSRMoussaF. [60] fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett2005; 5: 2578–2585.
92.
DuganLLTuretskyDMDuCLobnerDWheelerMAlmliCRShenCKFLuhTYChoiDWLinTS. Carboxyfullerenes as neuroprotective agents. Proc Natl Acad Sci U S A1997; 94: 9434–9439.
93.
ZogovicNSNikolicNSVranjes-DjuricSDHarhajiLMVucicevicLMJanjetovicKDMisirkicMSTodorovic-MarkovicBMMarkovicZMMilonjicSKTrajkovicVS. Opposite effects of nanocrystalline fullerene (C-60) on tumour cell growth in vitro and in vivo and a possible role of immunosupression in the cancer-promoting activity of C-60. Biomaterials2009; 30: 6940–6946.
94.
ChenY-WHwangKCYenC-CLaiY-L. Fullerene derivatives protect against oxidative stress in RAW 264.7 cells and ischemia-reperfused lungs. Am J Physiol Regul Integr Comp Physiol2004; 287: R21–R26.
95.
MitchellLLauerFBurchielSMcDonaldJ. Mechanisms for how inhaled multiwalled carbon nanotubes suppress systemic immune function in mice. Nat Nanotechnol2009; 4: 451–456.
96.
MitchellLAGaoJVander WalRGigliottiABurchielSWMcDonaldJD. Pulmonary and systemic immune response to inhaled multiwalled carbon nanotubes. Toxicol Sci2007; 100: 203–214.
97.
HerzogEByrneHJCaseyADavorenMLenzA-GMaierKLDuschlAOostinghGJ. SWCNT suppress inflammatory mediator responses in human lung epithelium in vitro. Toxicol Appl Pharmacol2009; 234: 378–390.
98.
TkachAVShurinGVShurinMRKisinERMurrayARYoungSHStarAFadeelBKaganVEShvedovaAA. Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure. ACS Nano2011; 5: 5755–5762.
99.
HardyCLLeMasurierJSBelzGTScalzo-InguantiKYaoJXiangSDKanellakisPBobikAStricklandDHRollandJMO’HehirREPlebanskiM. Inert 50-nm polystyrene nanoparticles that modify pulmonary dendritic cell function and inhibit allergic airway inflammation. J Immunol2012; 188: 1431–1441.
100.
FrickSUBacherNBaierGMailanderVLandfesterKSteinbrinkK. Functionalized polystyrene nanoparticles trigger human dendritic cell maturation resulting in enhanced CD4+T cell activation. Macromol Biosci2012; 2: 1637–1647.
BoschX. Dendrimers to treat rheumatoid arthritis. ACS Nano2011; 5: 6779–6785.
103.
ChauhanASDiwanPVJainNKTomaliaDA. Unexpected in vivo anti-inflammatory activity observed for simple, surface functionalized poly (amidoamine) dendrimers. Biomacromolecules2009; 10: 1195–1202.
104.
BoridySSolimanGMMaysingerD. Modulation of inflammatory signaling and cytokine release from microglia by celastrol incorporated into dendrimer nanocarriers. Nanomedicine2012; 7: 1149–1165.
105.
HayderMPoupotMBaronMNigonDTurrinCOCaminadeAMMajoralJPEisenbergRAFournieJJCantagrelAPoupotRDavignonJL. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci Transl Med2011; 3: 1–13.
TeoITomsSMMarteynBBarataTSSimpsonPJohnstonKASchnupfPPuharABellTTangCZlohMMatthewsSRendlePMSansonettiPJShaunakS. Preventing acute gut wall damage in infectious diarrhoeas with glycosylated dendrimers. EMBO Mol Med2012; 4: 866–881.
109.
ShuklaNMSalunkeDBBalakrishnaRMutzCAMalladiSSDavidSA. Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer. PLoS One2012; 7: e43612–e43612.
110.
HongYSLaksHCuiGGChongTSenLY. Localized immunosuppression in the cardiac allograft induced by a new liposome-mediated IL-10 gene therapy. J Heart Lung Transplant2002; 21: 1188–1200.
111.
KoSNakajimaYKanehiroHHorikawaMYoshimuraATakiJAomatsuYKinTYaguraKNakanoH. The enhanced immunosuppressive efficacy of newly developed liposomal Fk506 in canine liver-transplantation. Transplantation1995; 59: 1384–1388.
112.
MetselaarJMWaubenMHMWagenaar-HilbersJPABoermanOCStormG. Complete remission of experimental arthritis by joint targeting of glucocorticoids with long-circulating liposomes. Arthritis Rheum2003; 48: 2059–2066.
113.
BlackMTrentAKostenkoYLeeJSOliveCTirrellM. Self-assembled peptide amphiphile micelles containing a cytotoxic T-cell epitope promote a protective immune response in vivo. Adv Mater2012; 24: 3845–3849.
114.
MitchellDYongMRajuJWillemsenNBlackMTrentATirrellMOliveC. Toll-like receptor-mediated adjuvanticity and immunomodulation in dendritic cells: implications for peptide vaccines. Hum Vaccin2011; 7: 85–93.
115.
RudraJSTianYFJungJPCollierJH. A self-assembling peptide acting as an immune adjuvant. Proc Natl Acad Sci U S A2010; 107: 622–627.
116.
BregoliLChiariniFGambarelliASighinolfiGGattiAMSantiPMartelliAMCoccoL. Toxicity of antimony trioxide nanoparticles on human hematopoietic progenitor cells and comparison to cell lines. Toxicology2009; 262: 121–129.
117.
MatsumuraMTakasuNNagataMNakamuraKKawaiMYoshinoS. Effect of ultrafine zinc oxide (ZnO) nanoparticles on induction of oral tolerance in mice. J Immunotoxicol2010; 7: 232–237.
118.
GibaudSAndreuxJWeingartenCRenardMCouvreurP. Increased bone marrow toxicity of doxorubicin bound to nanoparticles. Eur J Cancer1994; 30: 820–826.
119.
DesaiN. Challenges in development of nanoparticle-based therapeutics. AAPS J2012; 14: 282–295.
ZajicovaAJavorkovaETrosanPKrulovaMHolanV. Drug-loaded nanofiber scaffolds for a simultaneous delivery of stem cells and immunosuppressive drugs in cell-based therapy and regenerative medicine. J Tissue Eng Regen Med2014; 8: 277–278.
122.
SaitoNHaniuHUsuiYAokiKHaraKTakanashiSShimizuMNaritaNOkamotoMKobayashiSNomuraHKatoHNishimuraNTarutaSEndoM. Safe clinical use of carbon nanotubes as innovative biomaterials. Chem Rev2014; 114: 6040–6079.
